Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026
Same author

Characteristics and outcome of intra-abdominal desmoid-type fibromatosis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

FIMBRIMENOP-2402 trial: evaluating fimbriectomy with delayed oophorectomy in patients with high-risk tubo-ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Nature medicine·2026
Same author

Post-operative pain after laparoscopy in gynecologic surgery: randomized trial on peritoneal gas drainage.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Association of immune relevant single nucleotide polymorphisms with ALK-positive anaplastic large cell lymphoma presentation and outcome: results of the immuno ALCL study.

Journal of translational medicine·2025

Related Experiment Video

Updated: Jul 18, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

[Neoadjuvant treatment in osteosarcomas].

Chantal Kalifa1, Laurence Brugières, Marie-Cécile Le Deley

  • 1Département de cancérologie de l'enfant et de l'adolescent, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex. kalifa@igr.fr

Bulletin Du Cancer
|December 6, 2006
PubMed
Summary

Chemotherapy significantly improves outcomes for limb osteosarcoma when combined with surgery. Further research is needed to optimize drug combinations and assess long-term toxicity for better patient survival.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Experiment Videos

Last Updated: Jul 18, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Area of Science:

  • Orthopedic Oncology
  • Medical Oncology
  • Pediatric Oncology

Context:

  • Osteosarcoma of the limbs historically had a poor prognosis with amputation alone.
  • Neoadjuvant chemotherapy is standard for micrometastasis eradication and limb-salvage surgery preparation.
  • Current limb-sparing surgery allows for a 50-80% relapse-free survival in most patients, including children.

Purpose:

  • To review the current role of chemotherapy in treating limb osteosarcoma.
  • To highlight controversies in neoadjuvant chemotherapy regimens and salvage chemotherapy efficacy.
  • To emphasize the need for prospective trials to address treatment optimization and drug toxicity.

Summary:

  • Chemotherapy, including high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide, dramatically improves limb osteosarcoma prognosis.
  • Limb-salvage surgery is now feasible for most patients, achieving 50-80% relapse-free survival.
  • Optimal drug combinations, the number of preoperative drugs, and salvage chemotherapy for poor responders require further investigation.

Impact:

  • Improved survival rates and limb preservation for osteosarcoma patients.
  • Informs ongoing research into optimizing chemotherapy regimens for osteosarcoma.
  • Highlights the importance of multi-center trials for advancing treatment protocols and managing long-term drug toxicity.